GET DAILY SIGNALSBlack Diamond Therapeutics (BDTX): Can It Hit the $10 Target for +400% Upside?
Key Takeaways
- The central $10 stock price target is the arithmetic mean of six current, attributable analyst price targets reviewed for this analysis, rounded from roughly $10.33.
- At a recent price near $2, reaching $10 would require an upside of roughly 400% — a very large move that is far beyond ordinary trading volatility.
- The verified individual analyst targets span a wide range from $8 to $14, reflecting genuine disagreement about the company's clinical and regulatory path.
- The strongest supporting factor is the lead drug candidate, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation EGFR (epidermal growth factor receptor) inhibitor in Phase 2 development.
- The biggest risks are the absence of product revenue, binary clinical-trial outcomes, potential dilution, and intense competition in targeted lung-cancer therapies.
- For more context, explore Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- To scan for changing market conditions across many names at once, explore Trending AI Robots.
Analyst Price Targets and Consensus View
In putting this review together, I examined six current, individually attributed analyst price targets. They range from a low of $8 to a high of $14, with an arithmetic mean of approximately $10.33 that rounds to a central target of $10. Independent sources such as S&P Global and MarketBeat report similar averages around $10 to $11, depending on the number of analysts included, so the $10 figure falls comfortably in the middle of published estimates.
The spread among targets highlights real differences in how analysts assess clinical risk. Wedbush’s Robert Driscoll has the highest at $14 (raised in March 2026), while Raymond James’ Sean McCutcheon and BTIG’s Robert Burns sit at $11. Jefferies’ Maury Raycroft maintains a $10 target and has called the catalyst setup “attractive.” More conservative views come from Stifel’s Laura Prendergast and Piper Sandler’s Kelsey Goodwin, both at $8. The overall stance remains a Moderate Buy to Strong Buy, though Guggenheim moved to a Hold in December 2025, showing the bullish view is not unanimous. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
BDTX shares have recently traded near $2, with recent closes between roughly $1.70 and $2.10 and the stock down more than 50% over the past year. From about $2, a move to $10 would imply upside of approximately 400%, best described as a very large move. The company reported no product revenue in its latest periods and remains pre-commercial, so any path to the target depends almost entirely on clinical data, regulatory feedback, and funding for silevertinib rather than near-term earnings momentum.
What Could Support a Move Toward the Target
The main catalyst remains silevertinib, which Black Diamond is advancing in non-small cell lung cancer and glioblastoma. Analysts at Jefferies and Raymond James have highlighted two near-term events: longer-term first-line follow-up data in non-classical EGFR-mutant NSCLC and regulatory feedback that could support a registrational trial. A durable response rate and good tolerability would strengthen the case for a potential best-in-class profile. The balance sheet provides some runway, with cash and investments intended to fund operations into 2027, and the latest quarterly loss per share beat expectations.
What Could Prevent the Target From Being Reached
As a clinical-stage biotech with no marketed product, Black Diamond carries binary risk. Disappointing trial data, safety concerns, or a delayed or rejected regulatory path could sharply reduce the valuation. Competition in EGFR-mutant NSCLC is intense, with multiple fourth-generation inhibitors in development. Dilution remains a concern, as additional equity raises would affect per-share value. The stock’s weak relative strength and low technical rating also suggest the market currently questions whether the higher analyst targets are reachable soon.
Technical Levels and Market Structure
For a low-priced, pre-revenue clinical-stage name trading near its 52-week low, meaningful technical levels are limited. The recent range of roughly $1.70 to $2.10 serves as a near-term reference, with the 52-week low as key support to watch. Because the $10 target sits well above any recent resistance, there is no established technical pathway of prior highs; reaching it would require sustained positive clinical news and a market re-rating rather than a simple breakout.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month horizon, though timelines for clinical-stage companies are inherently uncertain. Investors should watch for updated silevertinib efficacy and durability data, FDA feedback on the registrational path, quarterly cash and expense trends, any partnership or financing news, and further analyst target revisions. Clinical catalysts matter more than earnings dates here.
Final Assessment
Whether BDTX can reach $10 ultimately depends on whether silevertinib can deliver competitive clinical data and secure a clear registration path. The $10 central target, derived from the mean of six analyst targets spanning $8 to $14, implies roughly 400% upside from a price near $2 — a very large move that would require a decisive clinical or regulatory catalyst. Bullish analysts point to early durability signals and cash runway into 2027, while cautious voices highlight no revenue, binary risk, competition, and weak recent performance. The next data readouts and regulatory updates will be the key signposts, and no outcome is assured.
AI Daily Buy/Sell Signals
I have found Tickeron’s AI Daily Buy/Sell Signals helpful for monitoring thousands of stocks and ETFs in real time. The tool generates Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis, which can complement fundamental research when scanning for shifting trends or managing positions efficiently.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BDTX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BDTX turned positive on October 20, 2026. Looking at past instances where BDTX's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BDTX's RSI Indicator exited the oversold zone, 28 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +14.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDTX advanced for three days, in 198 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 51 cases where BDTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDTX as a result. In 57 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
BDTX moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BDTX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BDTX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BDTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.046) is normal, around the industry mean (3.037). P/E Ratio (-2.333) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (2.360) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. BDTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms.
Industry Biotechnology
Advertisement